Acquiring Company
Oculis Holding AG
Acquired Company
Accure Therapeutics S.L
Lausanne
BarcelonaBiotechnologyHealth CareTherapeuticsBiopharmaBiotechnologyHealth CareMedicalTherapeuticsDescription
Oculis Holding AG has entered an asset purchase agreement to acquire all worldwide development and commercial rights to Privosegtor from Accure Therapeutics. The transaction is structured into two closings, with an upfront payment of $3.8 million and up to 2,050,000 Oculis ordinary shares for Accure. This strategic acquisition will enhance Oculis' position in neuro-ophthalmology and facilitate future growth without legacy obligations.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Accure Therapeutics S.L?
Accure Therapeutics S.L was acquired by Oculis Holding AG, based in Lausanne. The deal was reported on August 10, 2026. Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis Holding AG is publicly traded (OCS) and operates in Biotechnology.
When did Oculis Holding AG acquire Accure Therapeutics S.L?
Oculis Holding AG's acquisition of Accure Therapeutics S.L was reported on August 10, 2026. Oculis Holding AG has entered an asset purchase agreement to acquire all worldwide development and commercial rights to Privosegtor from Accure Therapeutics. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Accure Therapeutics S.L do?
Accure Therapeutics is a private translational neuroscience R&D company working on innovative treatments. The firm focuses on developing therapies for various neurological conditions. It is privately held, operating in Biotechnology, and is based in Barcelona.